Quantification of proinflammatory cytokines in the urine of congestive heart failure patients. Its relationship with plasma levels

European Journal of Heart Failure

Volumn 5, Issue 1, 2003, Pages 27-31

  Sirera, Rafael ^a   Salvador, Antonio ^b   Roldán, Ildefonso ^b   Talens, Raquel ^a   González Molina, Andrés ^a   Rivera, Miguel ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Congestive heart failure; Cytokines; Interleukin 6; Tumor necrosis factor alpha; Urine

Indexed keywords

CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; STATISTICAL SIGNIFICANCE; URINALYSIS;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; STATISTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12244253759     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00165-4     Document Type: Article

References (35)

1. Mann DL, Young JB. Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 1994;105:897-904.
2. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S. Increased levels of cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 1994;72:561-6.
3. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
4. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. 1996;27:1201-6.
5. Kapadia S, Lee JR, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 1995;96:1042-52.
6. Torre-Amione G, Kapadia S, Lee J, Bies RD, Levobitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptor in human myocardium. Circulation 1995;92:1487-93.
7. Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin I and tumor necrosis factor inhibit cardiac myocyte β-adrenergic responsiveness. Proc. Natl. Acad. Sci. USA 1989;86:6753-7.
8. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. 1996;98:2854-65.
9. Boluyt MO, O'Neill L, Meredith AL, et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure: marked upregulation of genes encoding extracellular matrix components. Circ. Res. 1994;75:23-32.
10. Tsutamoto T, Wada A, Matsumoto T, et al. Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001;37:2086-92.
11. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
12. Petretta M, Condorelli GL, Spinelli L, et al. Circulating levels of cytokines and their site of production in patients with mild to severe chronic heart failure. Am. Heart. J. 2000;140:E28.
13. Meldrum DR. Tumor necrosis factor in the heart. Am. J. Physiol. 1998;274:577-95.
14. Gullestad L, Aukrust P, Ueland T, et al. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol. 1999;34:2061-7.
15. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarione, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-8.
16. Li D, Zhao L, Liu M, et al. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis alpha in acute myocardial infarction. Am. Heart. J. 1999;137:1145-52.
17. Louis A, Cleland JG, Crabbe S, et al. Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur. J. Heart Fail. 2001;3:381-7.
18. Gormley SM, McBride WT, Armstrong MA, et al. Plasma and urinary cytokine homeostasis and renal dysfunction during cardiac surgery. Anesthesiology 2000;93:1210-6.
19. European Society of Cardiology, Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. J. Heart Fail. 2002;4:11-22.
20. Cohn JN. The management of chronic heart failure. N. Engl. J. Med. 1996;335:490-8.
21. Remme WJ. Towards the better treatment of heart failure. Eur. Heart J. 1998;(Suppl L):L36-42.
22. Rivera S, Sattler FR, Boyd H, Auffenberg T, Nakao S, Moldawer LL. Urinary cytokines for assessing inflammation in HIV-wasting. Cytokine 2001;13:305-13.
23. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 1984;311:819-23.
24. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990;323:236-41.
25. Hegewish S, Weh H-J, Hossfeld DK. TNF-induced cardiomiopathy. Lancet 1990;2:294-5.
26. Maury CPJ, Teppo A-M. Circulating tumor necrosis factor-α (cachectin) in myocardial infarction. J. Intern. Med. 1989;225:333-6.
27. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J. Clin. Invest. 1993;92:2303-12.
28. Munger MA, Johnson B, Amber IJ, Callahan KS, Gilbert EM. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 1996;77:423-7.
29. Plenz G, Song ZF, Tjan TDT, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur. J. Heart Fail. 2001;3:415-21.
30. Kunisada K, Hirota H, Fujio Y, et al. Activation of JAK-STAT and MAP kinases by leukemia inhibitory factor through gp130 in cardiac myocytes. Circulation 1996;94:2626-32.
31. Dworkin LD, Brenner BM. Biophysical basis of glomerular filtration. In: Seldin DW, Giebish G, editors. 2nd ed., The kidney: physiology and pathophysiology. New York: Raven Press, 1992.
32. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J. Am. Coll. Cardiol. 1998;31:391-8.
33. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br. Heart J. 1993;70:141-3.
34. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J. Heart Lung Transplant 2000;19:819-24.
35. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000;141:1901-4.